Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Finance News Network Investor Event (October 2018)
18 slides from Kazia Therapeutics's conference presentation, Oct 11, 2018
Slide 1: Presentation to Finance News Network Investor Event (ASX release)
ASX RELEASE 11 October 2018 PRESENTATION TO FINANCE NEWS NETWORK INVESTOR EVENT Sydney, 11 October 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to release an investor presentation to be made today at the Finance News Net
Slide 2: Cancer-focused biotech with two clinical-stage programs
Cancer-focused biotech with two clinical-stage programs Presentation to Finance News Network Investor Event Sydney, NSW 11 October 2018 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 4: Investment Highlights
Investment Highlights Cancer drug developer with two distinct therapies in clinical trials 1 - GDC-0084 in phase II trial for brain cancer - Cantrixil in phase I trial for ovarian cancer Lead program, GDC-0084, acquired from Genentech following their 2 strategic deprioritisation and now in phase II
Slide 5: Kazia strategy to develop high-quality assets from external sources
Kazia strategy to develop high-quality assets from external sources Identify Value Build Value Realise Value • Conduct focused clinical trials • Bring in under- • Identify optimal • Partner with big valued assets patient groups pharma for late- from other • Understand safety stage development pharma
Slide 6: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 7: Two clinical programs, with value-driving inflection points during 2018-19
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018-19 ✓ ✓ GDC-0084 Commence Data read-out Data read-out Receipt of Start of phase potential from phase 2a from phase 2a Orphan Drug 2a study in collaborations study (safety study Designation Glioblastom
Slide 8: Kazia is NASDAQ & ASX listed with ~$9.3M of current assets at 30 June 2018
Kazia is NASDAQ & ASX listed with ~$9.3M of current assets at 30 June 2018 Share Price (AU$) KZA As at 30 June 2018 0.90 Current Assets Debt 0.80 AU$ 9.3 million Nil Market Capitalisation 0.70 AU$ 20.6 million (at 30 September 2018) 0.60 ASX: KZA Listing NASDAQ: KZIA (1:10 ratio) 0.50 0.42 ASX: 0.1%
Slide 9: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 10: There is increasing recognition of the need to find treatment options for GBM
There is increasing recognition of the need to find treatment options for patients diagnosed with GBM Growing public attention for brain cancer highlights need for new treatment options • Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new
Slide 11: Current standard of care is essentially ineffective in approximately 65% of GBM cases
Current standard of care is essentially ineffective in approximately 65% of GBM cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond GDC-0084 is being developed for
Slide 12: The PI3K inhibitor class is well-validated, but GDC-0084 is the only brain-penetrant drug in GBM
The PI3K inhibitor class is well-validated, but GDC-0084 is the only brain-penetrant drug in GBM Two marketed products in the PI3K class GDC-0084 is essentially unique in being able validate this approach to treating cancer to cross the blood-brain barrier • Two PI3K inhibitors now successfully brou
Slide 13: Phase I of GDC-0084 established dosing and showed favourable safety
Phase I of GDC-0084 established dosing and showed favourable safety Safety Efficacy Signals • Phase I safety trial conducted by GDC-0084 Comparison Genentech 40% 21-52% • 47 patients enrolled with advanced glioma (grade 3/4); average of Arresting Achieved in studies of three prior lines of therapy T
Slide 14: In GDC-0084 phase I, 7/27 patients showed a 'metabolic partial response' on FDG-PET
In GDC-0084 phase I, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084 Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory 12
Slide 15: Multipart GDC-0084 phase II design allows for frequent data read-outs
Multipart GDC-0084 phase II design allows for frequent data read-outs to inform partnering and early approval ‘Phase 2a’ Component Step 1 Step 2 Step 3 Dose Optimisation Expansion Cohort Planned Registration Trial 6 – 24 patients 20 patients 12 months 6 months March 1H 2H 2018 2019 2019 Dosing and s
Slide 16: Recent collaboration with St Jude expands GDC-0084 into childhood brain cancer
Recent collaboration with St Jude, a leading US paediatric hospital, expands GDC-0084 into childhood brain cancer Preclinical Phase I Phase II Phase III Glioblastoma Multiforme (GBM) (Kazia-sponsored) GDC-0084 PI3K / mTOR Diffuse Intrinsic Inhibitor Pontine Glioma (DIPG) (collaboration with St Jude
Slide 17: Investment Highlights
Investment Highlights Cancer drug developer with two distinct therapies in clinical trials 1 - GDC-0084 in phase II trial for brain cancer - Cantrixil in phase I trial for ovarian cancer Lead program, GDC-0084, acquired from Genentech following their 2 strategic deprioritisation and now in phase II
Slide 18: www.kaziatherapeutics.com
www.kaziatherapeutics.com [email protected]
Kazia Therapeutics — Finance News Network Investor Event (October 2018) on 6ix